4D Molecular Therapeutics Secures Major Otsuka Partnership, Advances Key Clinical Programs, and Reports Strong 2025 Financials

summarizeSummary

This annual report highlights a transformative year for 4D Molecular Therapeutics, marked by a significant strategic collaboration with Otsuka Pharmaceutical and substantial progress in its clinical pipeline. The $85.0 million upfront payment from Otsuka, with potential for up to $335.5 million in milestones and tiered double-digit royalties, provides crucial non-dilutive funding and validates the company's 4D-150 program for retinal vascular diseases. Positive interim data from multiple clinical trials for 4D-150 (wet AMD and DME) and 4D-710 (cystic fibrosis) further de-risk the pipeline and demonstrate the potential of their Therapeutic Vector Evolution platform. While the company reported a net loss, it was reduced from the prior year, and the cash position of $514.0 million provides a runway of at least one year. The workforce reduction, while a negative signal, reflects a strategic prioritization of key programs. The substantial capital raises in 2024 and 2025, including a $93.3 million offering in November 2025, indicate a continued need for funding but also the market's willingness to support the company's development efforts.

check_boxKey Events

• Major Strategic Partnership with Otsuka Pharmaceutical

  On October 31, 2025, 4D Molecular Therapeutics entered into a Collaboration and License Agreement with Otsuka Pharmaceutical Co., Ltd. for 4D-150 in Japan, China, Australia, and other Asia-Pacific markets. The deal includes an $85.0 million upfront cash payment, up to $335.5 million in potential regulatory and commercial milestone payments, and tiered double-digit royalties on net sales. 4DMT retains full development and commercialization rights outside the APAC region.

• Positive Clinical Progress for 4D-150 in Retinal Diseases

  The company reported positive long-term interim results from the PRISM Phase 1/2 clinical trial for 4D-150 in wet AMD in November 2025, showing consistent and durable benefit. Enrollment for the 4FRONT-1 Phase 3 trial in wet AMD was completed ahead of projections in February 2026, with topline data expected in H1 2027. Positive 60-week interim data for 4D-150 in DME from the SPECTRA Phase 1/2 trial in July 2025 led to FDA alignment for a single Phase 3 trial, expected to initiate in Q3 2026.

• Promising Early Clinical Data for 4D-710 in Cystic Fibrosis

  In December 2025, 4D Molecular Therapeutics announced positive interim clinical data from the AEROW Phase 1 trial for 4D-710 in cystic fibrosis, demonstrating dose-dependent CFTR transgene RNA levels, durable expression, and clinically meaningful activity. The Phase 2 dose was selected based on these results.

• Workforce Reduction and Pipeline Prioritization

  On July 2, 2025, the company announced a workforce reduction of approximately 25% of current and planned roles, primarily in early-stage research and development, to strategically prioritize the development of 4D-150 and 4D-710. This resulted in a $3.2 million expense.

auto_awesomeAnalysis

This annual report highlights a transformative year for 4D Molecular Therapeutics, marked by a significant strategic collaboration with Otsuka Pharmaceutical and substantial progress in its clinical pipeline. The $85.0 million upfront payment from Otsuka, with potential for up to $335.5 million in milestones and tiered double-digit royalties, provides crucial non-dilutive funding and validates the company's 4D-150 program for retinal vascular diseases. Positive interim data from multiple clinical trials for 4D-150 (wet AMD and DME) and 4D-710 (cystic fibrosis) further de-risk the pipeline and demonstrate the potential of their Therapeutic Vector Evolution platform. While the company reported a net loss, it was reduced from the prior year, and the cash position of $514.0 million provides a runway of at least one year. The workforce reduction, while a negative signal, reflects a strategic prioritization of key programs. The substantial capital raises in 2024 and 2025, including a $93.3 million offering in November 2025, indicate a continued need for funding but also the market's willingness to support the company's development efforts.